E4 engages uPAR and enolase-1 and activates urokinase to exert antifibrotic effects

Fibroproliferative disorders such as systemic sclerosis (SSc) have no effective therapies and result in significant morbidity and mortality. We recently demonstrated that the C-terminal domain of endostatin, known as E4, prevented and reversed both dermal and pulmonary fibrosis. Our goal was to iden...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Shailza, Watanabe, Tomoya, Nishimoto, Tetsuya, Takihara, Takahisa, Mlakar, Logan, Nguyen, Xinh-Xinh, Sanderson, Matthew, Su, Yunyun, Chambers, Roger A., Feghali-Bostwick, Carol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783693/
https://www.ncbi.nlm.nih.gov/pubmed/34935642
http://dx.doi.org/10.1172/jci.insight.144935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783693/
https://www.ncbi.nlm.nih.gov/pubmed/34935642
http://dx.doi.org/10.1172/jci.insight.144935

Ejemplares similares